Plaintiffs filed more than 350 products liability cases last month in Delaware state court against AstraZeneca Pharmaceuticals L.P. over the anti-psychotic drug Seroquel — a surge exceeding the total number of cases filed there in the last two years.

Plaintiffs lawyers contend that there is nothing behind the spike in filings. They point out that Delaware is Wilmington-based AstraZeneca’s home state and that the cases would have been filed eventually anyway.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]